A healthier microbiome supports GLP-1 activity and improves insulin sensitivity
One possible way to minimize the side-effects of the single drugs is to combine them to achieve synergistic effects, as reported recently with a combination of a DPP-IV inhibition, SSTR5 antagonism and GPR40 and TGR5 agonism, capable to raise circulatory active GLP-1(7-36) NH2 levels to more than 300-400 pM in mice (240)
This paper helps close that gap by providing evidence-based data that can be applied from prior weight loss science, while paving the way for future research combining GLP-1 and supplement interventions. According to the papers disclosure of interest, all authors are employed by GNC Holdings
The most clinically significant interaction concern involves antidiabetic medicines
CJC-1295 with DAC has a much longer half-life, leading to a sustained elevation of GH levels, often called a GH bleed. CJC-1295 without DAC (Mod GRF 1-29) has a shorter half-life, which better mimics the bodys natural pulsatile release of growth hormone when dosed correctly
A February 2024 study concluded that oral semaglutide may be most valuable as an add-on to the injectable form